Best thebodypro podcasts we could find (Updated April 2018)
Related podcasts: The Body Pro Medicine Science Hiv Research Hiv Aids  
Thebodypro public [search 0]
show episodes
HIV Frontlines
"HIV Frontlines" is an ongoing podcast series from in which we talk with the men and women who work at the forefront of HIV prevention, care and advocacy.
The Body PRO's podcast conference coverage features a diverse collection of interviews with top HIV researchers and clinicians. Largely conducted on-site at the most important HIV conferences, including the Conference on Retroviruses and Opportunistic Infections and the Interscience Conference on Antimicrobial Agents and Chemotherapy, as well as meetings of the International AIDS Society and the Infectious Diseases Society of America, these interviews feature summaries and analyses of key re ...
Loading …
show series
Since graduating college in the late '80s, Monique Howard has been working in the HIV/AIDS field. From examining specimens in a lab to implementing HIV risk reduction programming at Beth Israel Hospital to earning a graduate degree in human sexuality, her work has been grounded in understanding how HIV/AIDS impacts women. Now, Howard is the exe ...…
For the past 20-plus years, Gary Paul Wright has dedicated his life to fighting the AIDS epidemic in New York City. Wright, one of the founders of the House of Latex, worked for Gay Men's Health Crisis and New York City's Department of Education before starting his own organization, the African American Office of Gay Concerns (AAOGC), in Newark ...…
Debbie Hagins, M.D., is a very busy woman: Her HIV/AIDS clinic serves nearly 1,000 people in Georgia. But that doesn't stop her from giving her cell phone number to her patients, and even going to their houses to make sure they take their HIV medications. Because many of her patients are struggling financially, this kind of dedication can make ...…
When most people think of the island of Jamaica, they likely think of white-sand beaches, sunny skies and lilting accents. But as poet Kwame Dawes and MAC AIDS Fund Director Nancy Mahon explain in our latest edition of HIV Frontlines, Jamaica has deep underlying problems -- and HIV/AIDS is one of them.…
"Yes, babies are pretty, but they grow up to have sex ... and to potentially expose themselves to HIV," says HIV advocate Kai Chandler. Part of Chandler's work at the Children's Hospital of Philadelphia involves getting preteens and teens tested for HIV, as well as talking to them about some pretty heavy issues -- sexual risk, partner negotiati ...…
"I have to have an army of people helping me educate," says Vanessa Austin, HIV services outreach coordinator at Harlem Hospital Center in New York City. For Austin, the key to reaching the most people with her HIV advocacy work is training people to become "information warriors" who then spread messages about HIV prevention and testing to thei ...…
When we finally turn the tide against HIV among African Americans, it'll be thanks to people like Audria Russell. She's the HIV program coordinator at the nonprofit organization Women in Need in New York City. She's in charge of a support group that educates and empowers girls between the ages of 10 and 13.…
"It was a very eerie, depressing, anxiety-provoking period," recalls Anthony Fauci, M.D. "The very darkest years of my professional career." Dr. Fauci is recounting the early 1980s, when, as an infectious disease doc working for the U.S. National Institutes of Health in Maryland, he watched helplessly as people showed up at his hospital with a ...…
When Gil Robertson's brother Jeffrey tested positive in 1982, their family defied the norms of the time and immediately surrounded Jeffrey with love and support. Inspired by his family's experience, Robertson began gathering stories from dozens of African Americans about how HIV had altered their lives. The result is Not in My Family: AIDS in t ...…
When Mark King was 20, he moved to West Hollywood. It was the early 1980s, and King was set on pursuing his acting career and soaking up the gay scene. He never expected to find himself in the middle of the darkest time in the U.S. HIV epidemic, caring for close friends as they became sick and died, while struggling with his own diagnosis. In t ...…
In 2004, a single e-mail changed the course of Dr. Kathryn Anastos' life -- and in so doing, may have helped saved the lives of hundreds, if not thousands, of women and children in Rwanda. The e-mail came from a Rwandan activist group for women and children who were victims of the genocidal civil war that tore the country apart in 1994. Hundred ...…
You're in a porn shop -- but you're not there to buy Blazing Saddles: Hardcore Version. You're there to meet up with a man you don't even know, and the two of you plan to have sex like bunnies back where nobody can see. Except there's someone who knows what you're up to! A man passes by, hands you some condoms, and teaches you about HIV and oth ...…
Eric Daar, M.D., discusses emerging data from recently approved agents or agents available in expanded access.
Erna Kojic, M.D., discusses her research on the prevalence of cervical and anal HPV infection in HIV-infected women.
Michael Mugavero, M.D., discusses his study on how often patients at an HIV clinic in Birmingham miss their visits and why 40% of those patients missed a quarter or more of their appointments.
Chia-Ching Wang, M.D., discusses her study of menopausal and perimenopausal women, which looked at their mammograms and Pap smear results, cardiovascular risk factors and rates of osteoporosis, osteopenia and cardiovascular disease.
Christos Karatzios, M.D., discusses his study on the medical needs and social characteristics of adolescents infected with HIV early in life.
Turner Overton, M.D., discusses his research on whether women who start taking antiretrovirals to reduce the risk of perinatal transmission should continue antiretroviral therapy.
Jay Lalezari, M.D., discusses the BOSS study, the first randomized study to examine the use of a needle-free device for administration of Fuzeon (enfuvirtide, T-20).
Joseph Eron, M.D., discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced patients.
Joseph J. Eron, M.D., reviews highlights of ICAAC, including 48-week data on maraviroc, a head-to-head comparison of darunavir + ritonavir to lopinavir/ritonavir in treatment-naive patients, and the results of a study using interleukin-2 to delay HAART initiation.
Pablo Tebas, M.D., discusses why people who stop taking HIV meds are potentially at a greater risk for cardiovascular disease than if they remain on treatment.
Ben Young, M.D., Ph.D., reviews his presentation, which analyzes the impact of Viread (tenofovir) on the kidney function of people who already have kidney disease.
Trevor Hawkins, M.D., provides an update on his view of the most important studies presented at ICAAC, including data presented on CCR5 inhibitors, and the ARTEMIS trial, in which darunavir (TMC114, Prezista) + ritonavir (RTV, Norvir) compared favorably to lopinavir/ritonavir (LPV/r, Kaletra) in treatment-naive patients.…
Michael Silverman, M.D., discusses his poster on the declining prevalence of HIV in pregnant women in Zimbabwe -- a 41% drop that may be due to the country's declining economy.
Tristan Ferry, M.D., discusses his poster on incidence and risk factors for non-AIDS-defining, non-HAART-related severe clinical events.
Matthew Goetz, M.D. discusses his research on the impact of co-receptor tropism on disease progression in treatment-naive patients.
Prakash Sista, Ph.D. discusses how the presence of protease inhibitor mutation I50L is associated with HIV drug resistance to atazanavir (ATV, Reyataz) and increased susceptibility to other protease inhibitors in a variety of protease mutational backgrounds.
Roy Gulick, M.D., M.P.H., discusses the results of his two-year study on treatment-experienced patients taking vicriviroc (SCH 417690, SCH-D), a CCR5 inhibitor in development.
Joel Gallant, M.D., M.P.H., wraps up our daily recap series from the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity test ...…
Calvin J. Cohen, M.D., M.S., discusses the role of new agents in suppressing HIV.
Eric Daar, M.D., discusses what he considers to be the two big studies of IAS 2007, the ongoing debate about when-to-start treatment, and his own take on circumcision as prevention in the developed world.
Pietro Vernazza, M.D., offers his take on the when-to-start HIV treatment debate, circumcision and cardiovascular complications.
Edwin DeJesus, M.D., F.A.C.P., discusses data supporting the possibility that at least some cross-resistance occurs between the integrase inhibitors in development: elvitegravir (GS 9137) and raltegravir (MK-0518).
Benoit Marin discusses the association between CD4+ count and viral load and death due to non-AIDS causes.
Annette Sohn, M.D., summarizes her plenary presentation on pediatric treatment issues and answers questions about global pediatric HIV.
Jonathan Uy, M.D., discusses how the initiation of HAART at a CD4+ cell count of 350 cells/mm3 is associated with a lower prevalence of antiretroviral resistance mutations at virologic failure.
Pietro Vernazza, M.D., discusses his poster on pre-exposure prophylaxis and timed unprotected intercourse for HIV-discordant heterosexual couples wanting to conceive a child.
Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.
Trevor Hawkins, M.D., discusses the TITAN study, reviewing the relative side effects profiles of darunavir (TMC114, Prezista) + ritonavir (Norvir) and lopinavir/ritonavir (Kaletra), and the study's implications on clinical practice.
Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.
Steven G. Deeks, M.D., discussed SMART substudy results and weighed in on the when-to-start HIV treatment debate.
Anthony Mills, M.D., discusses the results of the DUET-1 trial, a double-blind, placebo-controlled, phase 3 trial designed to assess the efficacy and safety of TMC125 (etravirine) in treatment-experienced patients with NNRTI and PI resistance.
Nancy Padian, Ph.D., summarizes her plenary presentation on prevention technologies such as microbicides, dental dams and the female condom. Dr. Padian then answers questions on her presentation.
Daniel J. Skiest, M.D., discusses ACTG 5170 quality of life results showing that patients who had a high CD4+ cell count before a treatment interruption saw their medication-related symptoms improve during the treatment interruption.
Suraiya Rasheed, Ph.D., describes her research, which has shown that HIV infection of CD4+ cells enhances production of proteins associated with cardiovascular and other metabolic disorders.
Google login Twitter login Classic login